Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation due to Sepsis in a Compromised Patient: A Case Report

Kahori Morino; Yuichi Honma; Shinsuke Kumei; Tatsuyuki Watanabe; Keiichiro Kume; Ichiro Yoshikawa; Masaru Harada

doi:10.2169/internalmedicine.0633-17

This article has now been updated. Please use the final version.

Recombinant Thrombomodulin Used to Successfully Treat Cronkhite-Canada Syndrome with Disseminated Intravascular Coagulation due to Sepsis in a Compromised Patient: A Case Report

Kahori Morino, Yuichi Honma, Shinsuke Kumei, Tatsuyuki Watanabe, Keiichiro Kume, Ichiro Yoshikawa, Masaru Harada

Author information

Kahori Morino
Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, JAPAN
Yuichi Honma
Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, JAPAN
Shinsuke Kumei
Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, JAPAN
Tatsuyuki Watanabe
Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, JAPAN
Keiichiro Kume
Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, JAPAN
Ichiro Yoshikawa
Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, JAPAN
Masaru Harada
Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, JAPAN

Keywords: bacterial translocation, Cronkhite-Canada syndrome, disseminated intravascular coagulation, gastrointestinal polyposis, recombinant human soluble thrombomodulin, sepsis

JOURNAL OPEN ACCESS Advance online publication

Article ID: 0633-17

DOI https://doi.org/10.2169/internalmedicine.0633-17

The final version of this article is now available: Vol. 57 (2018), No. 21 pp. 3079-3085

Details

Abstract

Cronkhite-Canada syndrome (CCS) is a rare non-inherited disease characterized by gastrointestinal polyposis, chronic diarrhea, ectodermal dysplasia, skin hyperpigmentation, hair loss and nail atrophy. Although the efficacy of corticosteroid and immunomodulatory agents has been demonstrated, no standard therapy regimen has been established, and the prognosis of CCS is still poor due to various complications. We here in report a CCS patient complicated with severe sepsis and disseminated intravascular coagulation who was successfully treated by combined modality therapies, including recombinant human soluble thrombomodulin.

Corresponding author

Register with J-STAGE for free!